Alterity Therapeutics Reports Promising Phase 2 Results for MSA Treatment

Alterity Therapeutics ( (AU:ATH) ) has shared an update.

Alterity Therapeutics announced positive topline results from its open-label Phase 2 clinical trial of ATH434 in patients with multiple system atrophy (MSA). The trial demonstrated that ATH434 provides clinical benefits by stabilizing neurological symptoms and slowing brain atrophy, with a favorable safety profile. These findings are consistent with previous studies and support the advancement of ATH434 as a potential treatment for MSA, a disease currently lacking modifying medications. The results are promising for stakeholders, indicating potential progress in addressing this challenging condition.

More about Alterity Therapeutics

Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. The company is involved in creating therapies that target conditions such as multiple system atrophy (MSA), aiming to address unmet medical needs in this area.

YTD Price Performance: 60.0%

Average Trading Volume: 17,748,460

Technical Sentiment Signal: Sell

Current Market Cap: A$147.3M

For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.